GlaxoSmithKline cancer drug suffers setback By: MarketWatch March 20, 2014 at 05:24 AM EDT GlaxoSmithKline says Thursday that its MAGE-A3 cancer vaccine hadn’t met its first or second co-primary endpoints in its Phase III trial. Read More >> Related Stocks: Gsk Plc ADR